<SEC-DOCUMENT>0001213900-25-067797.txt : 20250725
<SEC-HEADER>0001213900-25-067797.hdr.sgml : 20250725
<ACCEPTANCE-DATETIME>20250725170002
ACCESSION NUMBER:		0001213900-25-067797
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250725
DATE AS OF CHANGE:		20250725

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CITIUS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0001851484
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93794
		FILM NUMBER:		251152258

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6677

	MAIL ADDRESS:	
		STREET 1:		420 LEXINGTON AVE,
		STREET 2:		SUITE 2446
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TenX Keane Acquisition
		DATE OF NAME CHANGE:	20210315

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Citius Pharmaceuticals, Inc. -->
          <cik>0001506251</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Shares, $0.0001 par value per share</securitiesClassTitle>
      <dateOfEvent>07/17/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001851484</issuerCIK>
        <issuerCUSIP>17331Y109</issuerCUSIP>
        <issuerName>Citius Oncology, Inc.</issuerName>
        <address>
          <com:street1>11 Commerce Drive</com:street1>
          <com:street2>1st Floor</com:street2>
          <com:city>Cranford</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07016</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Alexander M. Donaldson, Esq.</personName>
          <personPhoneNum>(919) 781-4000</personPhoneNum>
          <personAddress>
            <com:street1>Wyrick Robbins Yates &amp; Ponton LLP</com:street1>
            <com:street2>4101 Lake Boone Trail, Suite 300</com:street2>
            <com:city>Raleigh</com:city>
            <com:stateOrCountry>NC</com:stateOrCountry>
            <com:zipCode>27607</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001506251</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Citius Pharmaceuticals, Inc.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>66049615.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>66049615.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>66049615.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>84.3</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>CO</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Shares, $0.0001 par value per share</securityTitle>
        <issuerName>Citius Oncology, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>11 Commerce Drive</com:street1>
          <com:street2>1st Floor</com:street2>
          <com:city>Cranford</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07016</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>EXPLANATORY NOTE

On July 17, 2025, the Issuer sold and issued 6,818,182 shares of its common stock, $0.0001 par value per share, in a public offering.

This Amendment No. 1 to the Schedule 13D of the Reporting Person filed on August 16, 2024, amends and supplements the Schedule 13D as specifically set forth herein, to give effect to the issuance of the shares on July 17, 2025.</commentText>
      </item1>
      <item5>
        <percentageOfClassSecurities>The Reporting Person is the beneficial owner of 66,049,615 shares of the Issuer's common stock, which represents approximately 84.3% of the Issuer's outstanding common stock, based upon 78,370,402 shares of common stock outstanding as of July 17, 2025.</percentageOfClassSecurities>
        <numberOfShares>The Reporting Person has sole voting and dispositive power of 66,049,615 shares of the Issuer's common stock beneficially owned.</numberOfShares>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Citius Pharmaceuticals, Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Leonard Mazur</signature>
          <title>Leonard Mazur / Chief Executive Officer</title>
          <date>07/25/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
